Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.48 |
| ▸ | PPARA | Q07869 | 9/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709259 | 0.85 | ACACB (0.47) | PPARGPPARAEPHX2ACACBPPARD | |
| SCHEMBL1703013 | 0.83 | ACACB (0.48) | PPARGPPARAEPHX2ACACBELANE | |
| SCHEMBL20363264 | 0.81 | ACACB (0.52) | PPARGPPARAACACBELANELDHA | |
| SCHEMBL1709335 | 0.81 | ESR1 (0.47) | PPARGPPARAEPHX2 | |
| SCHEMBL1709341 | 0.79 | CYP1A2 (0.60) | PPARGEPHX2 | |
| SCHEMBL20363241 | 0.79 | ACACB (0.50) | PPARGPPARAACACBELANELDHA | |
| SCHEMBL27420078 | 0.78 | ACACB (0.49) | PPARGPPARAACACBELANELDHA | |
| SCHEMBL1709306 | 0.75 | HTR2A (0.47) | — | |
| SCHEMBL27422712 | 0.74 | ACACB (0.46) | PPARGPPARAACACBELANELDHA | |
| SCHEMBL4620389 | 0.74 | LDHA (0.55) | PPARGPPARAEPHX2ACACBLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | PPARG 773/4885PPARA 766/4885EPHX2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.